Abstract
Introduction Often, an isolated clinical event suggestive of CNS demyelination confers a risk of conversion to multiple sclerosis. In this study, we investigate lymphocyte profiles after a first clinical event suggestive of multiple sclerosis (MS), which could contribute to the current understanding of early inflammatory responses in this demyelinating disease.
Methods Twenty treatment-naïve clinically isolated syndrome (CIS) patients and fifteen healthy participants were included in our assessment of lymphocyte profiles and B cell subsets using multicolour flow cytometry. Analysis was made at 3-6 months (Baseline), 12, and 24 months after a first clinical event. We also performed a sub-analysis of patients that received glatiramer acetate (GLAT) after their baseline visit up to 24 months after the first clinical event.
Results Our analysis revealed monocyte and B cell differences between groups. Percentages of CD19+CD20+ B cells were lower in CIS patients compared to healthy individuals at baseline. Additionally, monocyte distribution among groups was different. A subgroup analysis of patients treated with GLAT (n= 10) showed an increased percentage of naïve (p<0.05) and memory pre-switched (p<0.01) B cells up to 24 months after their baseline visit compared to the untreated group (n= 10).
Conclusion Our results showed early monocyte and B cell subsets alterations in pwCIS. Moreover, GLAT-treated patients showed an increased percentage of naïve and memory pre-switched B cells after 24 months of treatment. Further research is needed to elucidate the role of B cells and monocyte disturbances during inflammatory processes after a first clinically-MS suggestive event.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CAG has received funding from the Mexican Government agency CONACYT (National Council of Science and Technology) for this project. AW, TD, and SS declare to have no conflict of interest. MSC has received fellowships from the Bayer Foundation and the Deutscher Akademischer Austauschdienst (DAAD) for her PhD studies. CC received speaker and writing honoraria from Bayer and the British Society of Immunology, research support from Novartis and Alexion, unrelated to this current study. CC is a member of the Standing Committee on Science for the Canadian Institutes of Health Research. JK received congress registration fees from Biogen and speaker honoraria from Sanofi Genzyme and Bayer Schering. SA received congress registration fees from Biogen, and speaker honoraria from Alexion, Roche and Bayer Schering. KR received research support from Novartis, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charite (BIH Clinical Fellow Program) and Arthur Arnstein Foundation; received travel grants from Guthy-Jackson Charitable Foundation. CID reports research grants from Novartis, Sanofi Genzyme and Deutsche Forschungsgemeinschaft (DFG; German Research Council) as well as conference honoraria from Sanofi Genzyme and Novartis. JBS has received speaking honoraria and travel grants from Bayer Healthcare, and sanofi- aventis/Genzyme, in addition received compensation for serving on a scientific advisory board of Roche, unrelated to the presented work. FP Reports research grants from German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche, Parexel and Almirall. Payment honoraria from Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene. Support attending meetings from Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene. All unrelated to the present work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent and ethics approval for this study was given by the institutional review board of Charite Universitatsmedizin Berlin (EA1/180/10).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* First joint authors
↵** Joint senior authors
We have carefully reviewed this second version and made the necessary revisions. Again, we would like to emphasise that in line with the exploratory nature of this study, we have made changes to the required sections and added supplementary information for better understanding. The changes made were: - A statistician is now included and co-authored during the reviewing and preparation of this work. We have used this input to address some statistical concerns. Per his recommendation we have performed ANCOVA analyses to evaluate the difference of quantified cell populations between GLAT and untreated patients, while controlling for baseline and 12-month quantifications as covariates. This approach enabled us to test for differences at 24 months without influence from prior quantifications. As we have included ANCOVA test and made the changes in the text accordingly, we have left these figures in the supplementary information as descriptive only graphs for better visualisation. The figures do not have any p values as ANCOVA results are presented entirely in Table 3 in the manuscript. In our ANCOVA analysis, we compared the treated-GLAT group with the untreated- GLAT group within all pwCIS participants at 24-month post-baseline, while controlling for baseline and 12-month measurements as covariates. By including baseline and 12- month measurements as covariates, we accounted for variations in baseline status and changes during the first year, thus insolating the effect of treatment at the 24-month time point. Although it appears that treatment was not included as a covariate in Table 3, this is because the focus of the model was on comparing the effect of treatment at 24 months, rather than controlling for treatment as confounder. Therefore, treatment is the main explanatory variable in the model, not a covariate.
Data Availability
The datasets generated and/or analysed during the current study are not publicly available due to local regulations concerning the protection of patient data, but upon reasonable request, approval for distribution of data will be obtained from the institutional review board of Charite-Universitatsmedizin Berlin and anonymised data will be made available by the corresponding authors.
